A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. Study investigators aim to enroll more than 500 people from clinical research sites nationwide. Interested volunteers can visit the ACTG website (clinical trial A5418) for more information.
U.S. clinical trial evaluating antiviral for monkeypox begins
September 11, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022